I Missing
1 -1.4 ± 1.4 -4.0 ± 0.7 -3.7 ± 1.0 -2.8 ± 0.7 -1.8 ± 1.7 -2.0 ± 0.4 0.0 ± 0.0 2 -4.4 ± 3.2 -7.7 ± 1.3 -7.0 ± 1.5 -5.9 ± 1.0 -4.2 ± 3.4 -3.3 ± 0.6 -0.1 ± 0.1 3 -8.7 ± 4.3 -10.4 ± 2.1 -9.7 ± 1.3 -9.1 ± 2.7 -5.9 ± 4.0 -4.1 ± 0.7 -0.4 ± 0.3 Day 2 1 -1.4 ± 1.4 -3.9 ± 0.7 -3.5 ± 1.0 -2.7 ±0.7 -1.7 ±1.6 -1.9 ± 0.5 0.0 ± 0.0 2 -4.2 ± 2.9 -7.5 ± 1.3 -6.7 ± 1.5 -5.6 ±1.0 -4.0 ± 3.4 -3.2 ± 0.6 -0.1 ± 0.1 3 -8.0 ± 4.0 -10.2 ± 2.0 -9.3 ± 1.4 -8.7 ± 2.6 -5.7 ± 3.9 -4.0 ± 0.7 -0.3 ± 0.4 Day 4 1 -1.4 ± 1.3 -3.8 ± 0.7 -3.4 ± 0.9 -2.6 ± 0.7 -1.6 ± 1.5 -1.9 ± 0.5 0.0 ± 0.0 2 -4.0 ± 2.7 -7.4 ± 1.2 -6.5 ± 1.4 -5.4 ± 1.0 -3.9 ± 3.2 -3.1 ± 0.6 -0.1 ± 0.1 3 -7.3 ± 3.8 -9.9 ± 2.0 -9.0 ± 1.4 -8.4 ± 2.5 -5.5 ± 3.8 -4.0 ± 0.7 -0.3 ± 0.3 Table 1 . Results of the dosimetric and radiobiological effect of central seed loss through the urethra for implants with I-125 seeds. Presented as a difference from original plans. 
